KIMMTRAK (tebentafusp)
Metastatic Uveal Melanoma
ApprovedCommercial
Key Facts
About Immunocore
Immunocore is a UK-based, publicly traded biotech focused on developing transformative T cell receptor-based immunotherapies. Its core achievement is the 2022 launch of KIMMTRAK (tebentafusp), the first-ever approved TCR therapy, for metastatic uveal melanoma. The company is advancing a broad pipeline of bispecific candidates across oncology, virology (HBV, HIV), and autoimmunity using its modular ImmTAX platform, positioning it as a leader in next-generation targeted immunomodulation.
View full company profileTherapeutic Areas
Other Metastatic Uveal Melanoma Drugs
| Drug | Company | Phase |
|---|---|---|
| RP2 + nivolumab | Replimune | Phase 2/3 |
| FHD-286 | Foghorn Therapeutics | Phase 1 |